Sicart Associates LLC Has $7.89 Million Stock Position in Illumina, Inc. $ILMN

Sicart Associates LLC grew its holdings in Illumina, Inc. (NASDAQ:ILMN) by 45.8% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 83,123 shares of the life sciences company’s stock after purchasing an additional 26,118 shares during the period. Illumina comprises approximately 2.1% of Sicart Associates LLC’s investment portfolio, making the stock its 17th biggest holding. Sicart Associates LLC owned approximately 0.05% of Illumina worth $7,894,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in ILMN. Corvex Management LP increased its stake in Illumina by 125.2% in the 1st quarter. Corvex Management LP now owns 3,829,608 shares of the life sciences company’s stock valued at $303,841,000 after buying an additional 2,129,449 shares during the last quarter. AQR Capital Management LLC boosted its stake in shares of Illumina by 361.7% during the 1st quarter. AQR Capital Management LLC now owns 2,121,585 shares of the life sciences company’s stock worth $165,484,000 after buying an additional 1,662,093 shares during the last quarter. Jacobs Levy Equity Management Inc. grew its holdings in shares of Illumina by 11,714.9% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 1,161,882 shares of the life sciences company’s stock valued at $92,184,000 after acquiring an additional 1,152,048 shares in the last quarter. Edmond DE Rothschild Holding S.A. increased its position in shares of Illumina by 140.1% in the second quarter. Edmond DE Rothschild Holding S.A. now owns 1,428,692 shares of the life sciences company’s stock valued at $136,312,000 after acquiring an additional 833,750 shares during the last quarter. Finally, Thrivent Financial for Lutherans increased its position in shares of Illumina by 1,558.0% in the second quarter. Thrivent Financial for Lutherans now owns 728,755 shares of the life sciences company’s stock valued at $69,528,000 after acquiring an additional 684,802 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on the company. Wall Street Zen upgraded Illumina from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Canaccord Genuity Group upped their price objective on Illumina from $105.00 to $112.00 and gave the stock a “hold” rating in a research note on Friday, October 31st. Barclays raised their target price on shares of Illumina from $100.00 to $110.00 and gave the company an “underweight” rating in a research note on Monday. Evercore ISI boosted their target price on shares of Illumina from $132.00 to $142.00 and gave the stock an “outperform” rating in a report on Friday, October 31st. Finally, Cowen reaffirmed a “hold” rating on shares of Illumina in a research report on Friday, October 31st. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, thirteen have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Illumina has a consensus rating of “Hold” and a consensus price target of $117.19.

Insider Transactions at Illumina

In related news, Director Scott Gottlieb purchased 500 shares of the firm’s stock in a transaction that occurred on Monday, November 3rd. The shares were acquired at an average price of $122.13 per share, for a total transaction of $61,065.00. Following the purchase, the director owned 12,523 shares in the company, valued at approximately $1,529,433.99. This represents a 4.16% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Scott M. Davies sold 323 shares of the firm’s stock in a transaction that occurred on Friday, December 12th. The stock was sold at an average price of $136.09, for a total transaction of $43,957.07. Following the sale, the insider owned 17,887 shares of the company’s stock, valued at $2,434,241.83. This trade represents a 1.77% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.17% of the stock is currently owned by corporate insiders.

Illumina Stock Down 2.5%

ILMN stock opened at $131.56 on Wednesday. Illumina, Inc. has a 1-year low of $68.70 and a 1-year high of $153.06. The business’s 50 day simple moving average is $116.09 and its 200 day simple moving average is $103.59. The company has a current ratio of 1.43, a quick ratio of 1.12 and a debt-to-equity ratio of 0.42. The firm has a market capitalization of $20.10 billion, a PE ratio of 29.50, a PEG ratio of 2.41 and a beta of 1.44.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, October 30th. The life sciences company reported $1.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.16 by $0.18. Illumina had a return on equity of 29.21% and a net margin of 16.40%.The business had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.07 billion. During the same quarter last year, the firm posted $1.14 EPS. The company’s quarterly revenue was up .4% on a year-over-year basis. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. As a group, research analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.